The Pharma Data

OCTOBER 28, 2020

government to supply 300,000 vials of bamlanivimab (LY-CoV555) 700 mg, an investigational neutralizing antibody, for $375 million. The supply of Lilly’s antibody therapy is expected to increase substantially beginning in Q1 2021, as additional manufacturing resources come online throughout the year. INDIANAPOLIS, Oct.

Antibody 40

Antibody Medicine Manufacturing Scientist 40

The Pharma Data

APRIL 3, 2021

The CoVIg-19 Plasma Alliance today announced that the Phase 3 Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) clinical trial sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), did not meet its endpoints.

Clinical Trials 52

Clinical Trials Clinical Trials Medicine Trials 52

XTalks

OCTOBER 26, 2023

The Flu versus COVID-19: Virology and Vaccines SARS-CoV-2 versus Influenza Virology Viruses contain genetic material that can either be RNA or DNA. For measles, the correlate of protection is having a certain concentration of antibodies in your system that will generally provide protection from getting measles infection.

Vaccination 105

Vaccination Vaccine RNA Manufacturing 105

The Pharma Data

JANUARY 24, 2021

It inked a deal with the National Institute of Allergy and Infectious Diseases (NIAID) to launch a Phase I trial. National Institute of Allergy and Infectious Diseases (NIAID), of bamlanivimab (LY-CoV555) decreased the risk of COVID-19 among residents and staff of long-term care facilities, i.e., nursing homes. Non-COVID-19-Related.

Trials 52

Trials Allergies In-Vitro Antibody 52

The Pharma Data

JULY 8, 2021

” “Current data for the eight months studied so far show that the single-shot Johnson & Johnson COVID-19 vaccine generates a strong neutralizing antibody response that does not wane; rather, we observe an improvement over time. ” Demonstrated strong neutralizing antibody activity against the Delta (B.1.617.2)

Vaccine 52

Vaccine Vaccination Immune Response Antibody 52

The Pharma Data

JULY 6, 2021

Current data for the eight months studied so far show that the single-shot Johnson & Johnson COVID-19 vaccine generates a strong neutralizing antibody response that does not wane; rather, we observe an improvement over time. Demonstrated strong neutralizing antibody activity against the Delta (B.1.617.2) 1.351), the Gamma (P.1)

Vaccination 52

Vaccination Vaccine Immune Response Antibody 52

The Pharma Data

DECEMBER 8, 2020

and is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. About Moderna.

Vaccine 40

Vaccine Vaccination Manufacturing Containment 40

The Pharma Data

JANUARY 19, 2021

The South African and other variants could very well evade the protection of antibody treatments and also bring up concerns about the efficacy of the current COVID-19 vaccines. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Production 52

Production Trials Containment Vaccine 52

The Pharma Data

MARCH 24, 2021

It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein. The NIAID-supported COVID-19 Prevention Network (CoVPN) participated in the trial. Source link:[link].

Vaccine 52

Vaccine Vaccination Radiology Trials 52

Pfizer

DECEMBER 8, 2022

The vaccine candidate is based on BioNTech’s proprietary mRNA platform technology and contains mRNA strands encoding the wild-type spike protein of SARS-CoV-2 and the spike protein of the Omicron sublineages BA.4/BA.5, Tell your vaccination provider about all of your medical conditions, including if you: have any allergies. INDICATION.

Vaccination 81

Vaccination Vaccine Clinical Trials Clinical Trials 81

Pfizer

NOVEMBER 2, 2022

The vaccine candidate is based on BioNTech’s proprietary mRNA platform technology and contains mRNA strands encoding the wild-type spike protein of SARS-CoV-2 and the spike protein of the Omicron BA.4/BA.5 Tell your vaccination provider about all of your medical conditions, including if you: have any allergies. INDICATION.

Vaccination 85

Vaccination Vaccine Clinical Trials Clinical Trials 85

The Pharma Data

JUNE 25, 2021

The CDC has defined Variant of Interest (VoI) as a variant with genetic markers that have been associated with changes to receptor binding, reduced neutralization by antibodies generated against previous infection or vaccination, or predicted increase in transmissibility or disease severity. BARDA is providing up to $1.75 About NVX-CoV2373.

Vaccine 40

Vaccine Vaccination Trials Immune Response 40

The Pharma Data

NOVEMBER 17, 2020

It currently has several vaccines in its pipeline, among which are the HIV-1/AIDS, intra-nasal Influenza and malaria, and collaborative projects in the field of allergy immunotherapy and in oncology. ” About Mymetics.

Vaccine 40

Vaccine Vaccination Containment Development 40

The Pharma Data

MARCH 22, 2021

It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein. The NIAID-supported COVID-19 Prevention Network (CoVPN) participated in the trial. Source link:[link].

Trials 52

Trials Vaccine Vaccination Radiology 52

The Pharma Data

MAY 4, 2021

Monoclonal antibodies, such as bamlanivimab and etesevimab, may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation. Point mutations were introduced into the native human IgG1 antibody to mitigate effector function.

Antibody 52

Antibody Medicine FDA Approval Licensing 52

Pfizer

JANUARY 27, 2023

This research provides a way for us to rapidly assess the ability of an existing vaccine to induce antibodies that neutralize a newly identified variant of concern. This work is undertaken once a new variant of concern has been identified by public health authorities.

Research 112

Research Vaccine Vaccination Drugs 112

The Pharma Data

DECEMBER 23, 2020

Stanley Plotkin , Professor Emeritus at The Wistar Institute, said, “INOVIO’s DNA vaccine appeared to be quite safe with few significant reactions but yet induced both antibody and T cell responses to SARS-CoV-2.” mg dose group and 84% demonstrating neutralizing antibodies in the 2.0 mg and 2.0 The 1.0

DNA 40

DNA Vaccine Vaccination Immune Response 40

The Pharma Data

APRIL 27, 2021

to €283 million, reflecting growth of Digestive and Mental Wellness categories as well as Allergy partially offset by the decline of the Pain category. Development for Dupixent ® for grass allergy has been discontinued. SAR440234 , T cell engaging multi specific antibody, has been discontinued in leukemia. Consumer Healthcare.

Sales 52

Sales Vaccine Vaccination Medicine 52

XTalks

AUGUST 2, 2023

It contains the antiviral medications nirmatrelvir and ritonavir. 2) Darzalex (daratumumab) Darzalex is a targeted monoclonal antibody that slows or stops the progression of multiple myeloma (a blood cancer) by binding to the CD38 protein on multiple myeloma cells. Pfizer’s total global revenue from Paxlovid was $18.93 billion in 2022.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

Pfizer

SEPTEMBER 28, 2022

Monovalent refers to any authorized and approved COVID-19 vaccine that contains or encodes the spike protein of only the Original SARS-CoV-2 virus . The information contained in this release is as of September 28, 2022. . • receipt of the most recent booster dose with any authorized or approved monovalent COVID-19 vaccine. .

Vaccination 101

Vaccination Vaccine Medicine Clinical Trials 101

Pfizer

JULY 8, 2022

A two-dose primary series of the vaccine (30-µg dose) elicited SARS-CoV-2–neutralizing antibody geometric mean titers (GMTs) of 1,239.5, Tell your vaccination provider about all of your medical conditions, including if you: have any allergies. The information contained in this release is as of July 8, 2022. have a fever.

FDA Approval 102

FDA Approval Vaccination Vaccine Clinical Trials 102

Pfizer

JULY 26, 2022

Tell your vaccination provider about all of the vaccine recipient’s medical conditions, including if the vaccine recipient: has any allergies. The information contained in this release is as of July 27, 2022. IMPORTANT SAFETY INFORMATION . has a fever. has a bleeding disorder or are on a blood thinner. Pfizer Disclosure Notice.

Vaccination 111

Vaccination Vaccine Protein Immune Response 111

Pfizer

JULY 19, 2022

Tell your vaccination provider about all of the vaccine recipient’s medical conditions, including if the vaccine recipient: has any allergies. The information contained in this release is as of July 19, 2022. IMPORTANT SAFETY INFORMATION. has a fever. has a bleeding disorder or are on a blood thinner. Pfizer Disclosure Notice.

Vaccination 100

Vaccination Vaccine Medicine Clinical Trials 100

XTalks

JANUARY 27, 2021

The company used in vitro neutralization antibody studies to evaluate the activity of Moderna’s vaccine-generated antibodies in human sera against several variants of the novel coronavirus, including the B.1.1.7 The in vitro study evaluated the ability of mRNA-1273-generated antibodies to neutralize the new SARS-CoV-2 variants.

Vaccine 52

Vaccine Vaccination In-Vitro Protein 52

The Pharma Data

NOVEMBER 9, 2020

About Tezepelumab Tezepelumab is an investigational, potential first-in-class human monoclonal antibody that works on the primary source of inflammation: the airway epithelium, which is the first point of contact for viruses, allergens, pollutants, and other environmental insults. 10 World Allergy Organization (WAO).

Trials 52

Trials Production Sales Manufacturing 52

The Pharma Data

JANUARY 29, 2021

1.351 and P1, respectively — contain a mutation called E484K, “which results in changes in the shape of the virus spike protein such that neutralizing antibodies might not bind as well as it does in the absence of the mutation,” explained Dr. Jay Butler, deputy director for infectious diseases at the U.S. FRIDAY, Jan.

Vaccine 52

Vaccine Vaccination Antibody Immune Response 52

The Pharma Data

JANUARY 12, 2021

Virology, Respiratory, Dermatology, Allergy, & Rheumatology) in early & late stage Clinical Development and in Medical Affairs, with a strong track record for Developing and Accelerating Phase I–IV programs. THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014.

Life Science 52

Life Science Antibody In-Vivo In-Vitro 52

The Pharma Data

DECEMBER 21, 2020

About Tezepelumab Tezepelumab is an investigational, potential first-in-class human monoclonal antibody that works on the primary source of inflammation: the airway epithelium, which is the first point of contact for viruses, allergens, pollutants, and other environmental insults. Amgen will record sales in the U.S. Outside the U.S.,

Trials 40

Trials Production Sales Manufacturing 40

The Pharma Data

JANUARY 29, 2021

1.351 and P1, respectively — contain a mutation called E484K, “which results in changes in the shape of the virus spike protein such that neutralizing antibodies might not bind as well as it does in the absence of the mutation,” explained Jay Butler, M.D., FRIDAY, Jan. health officials said Friday.

Vaccine 52

Vaccine Vaccination Allergies Containment 52

The Pharma Data

JANUARY 4, 2021

The Moderna COVID-19 Vaccine is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein, which was co-developed by Moderna and investigators from National Institute of Allergy and Infectious Diseases’ (NIAID) Vaccine Research Center. To learn more, visit www.modernatx.com. Forward Looking Statements.

Vaccine 40

Vaccine Vaccination Medicine Containment 40

The Pharma Data

APRIL 28, 2021

About Dupixent Dupixent is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant. This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended.

Dermatology 40

Dermatology Trials Clinical Trials Clinical Trials 40

Pfizer

JULY 8, 2022

IMPORTANT SAFETY INFORMATION Tell your vaccination provider about all the vaccine recipient’s medical conditions, including if the vaccine recipient: has any allergies. The information contained in this release is as of July 8, 2022. has a fever. has bleeding disorder or is on a blood thinner. has received another COVID-19 vaccine.

Vaccination 81

Vaccination Vaccine Clinical Trials Clinical Trials 81

Pfizer

SEPTEMBER 16, 2022

The third dose was well tolerated with a favorable safety profile and generated neutralizing antibodies against both Omicron and the original wild-type virus, regardless of prior COVID-19 diagnosis. Tell your vaccination provider about all of your medical conditions, including if you: have any allergies. have a fever.

Marketing 75

Marketing Vaccination Vaccine Clinical Trials 75

Pfizer

OCTOBER 19, 2022

Monovalent refers to any authorized and approved COVID-19 vaccine that contains or encodes the spike protein of only the Original SARS-CoV-2 virus. Tell your vaccination provider about all of your medical conditions, including if you: have any allergies. The information contained in this release is as of October 19, 2022.

Vaccination 40

Vaccination Vaccine Clinical Trials Clinical Trials 40

The Pharma Data

FEBRUARY 8, 2021

Allergy Cough & Cold. to €238 million, reflecting growth in the Allergy (Allegra ® and Xyzal ® ) and Digestives categories. sales decreased 1.6%, reflecting the impact of the Zantac ® recall which offset the growth in the Allergy and Nutritionals categories. Full-year 2020, BOI of Vaccines increased 4.4% (up 11.2%

Sales 52

Sales Vaccine Vaccination Production 52

The Pharma Data

FEBRUARY 4, 2021

Allergy Cough & Cold. to €238 million, reflecting growth in the Allergy (Allegra ® and Xyzal ® ) and Digestives categories. sales decreased 1.6%, reflecting the impact of the Zantac ® recall which offset the growth in the Allergy and Nutritionals categories. Full-year 2020, BOI of Vaccines increased 4.4% (up 11.2%

Sales 52

Sales Vaccine Vaccination Production 52

XTalks

FEBRUARY 4, 2021

Abionic first developed abioSCOPE in 2010 for allergy testing, and subsequently for sepsis and infection. Dr. Durand explains how “Abionic started with allergy testing [and] also developed tests for iron deficiency and other things. The air of a hospital is not so clean and contains bacteria.”. Validated Sepsis Biomarker.

Allergies 98

Allergies Bacteria Development Containment 98